Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.

[en] Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or epitopes. In the last few decades, BsAbs have been developed within the context of cancer therapies and in particular for the treatment of hematologic B-cell malignancies. To date, more than one hundred different BsAb formats exist, including bispecific T-cell engagers (BiTEs), and new constructs are constantly emerging. Advances in protein engineering have enabled the creation of BsAbs with specific mechanisms of action and clinical applications. Moreover, a better understanding of resistance and evasion mechanisms, as well as advances in the protein engineering and in immunology, will help generating a greater variety of BsAbs to treat various cancer types. This review focuses on T-cell-engaging BsAbs and more precisely on the various BsAb formats currently being studied in the context of B-cell malignancies, on ongoing clinical trials and on the clinical concerns to be taken into account in the development of new BsAbs.

Research Center/Unit :

Laboratoire d'Hématologie

Disciplines :

Hematology

Author, co-author :

Lejeune, Margaux ; Université de Liège - ULiège > I3-Hematology

Köse, Murat Cem ; Université de Liège - ULiège > I3-Hematology

Duray, Elodie ; Université de Liège - ULiège > GIGA

Einsele, Hermann

Beguin, Yves ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie

Caers, Jo ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.

Alternative titles :

[fr] Anticorps bispécifiques recruteurs de cellules T dans les tumeurs malignes à cellules B.

Publication date :

07 May 2020

Journal title :

Frontiers in Immunology

eISSN :

1664-3224

Publisher :

Frontiers Research Foundation, Lausanne, Switzerland

Volume :

Issue :

762

Pages :

1-20

Peer reviewed :

Peer Reviewed verified by ORBi

Name of the research project :

Amélioration de la mort cellulaire à l'aide d'anticorps dans le myélome multiple

Funders :

F.R.S.-FNRS - Fonds de la Recherche Scientifique

Available on ORBi :

since 29 June 2020

Statistics

Number of views

162 (18 by ULiège)

Number of downloads

400 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM., Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. (1985) 316:354–6. 3160953
De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A, et al. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J Hematother. (1995) 4:433–7. 8581381
Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. (2010) 127:2209–21. 10.1002/ijc.25423 20473913
Spiess C, Zhai Q, Carter PJ., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. (2015) 67(2 Pt A):95–106.
Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. (2017) 376:836–47. 10.1056/NEJMoa1609783 28249141
Brinkmann U, Kontermann RE., The making of bispecific antibodies. MAbs. (2017) 9:182–212. 10.1080/19420862.2016.1268307 28071970
Foster LH, Lum LG., Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs. Expert Opin Biol Ther. (2019) 19:707–20. 10.1080/14712598.2019.1604672 31081696
Thakur A, Huang M, Lum LG., Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. (2018) 32:339–47. 10.1016/j.blre.2018.02.004 29482895
Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. (2016) 29:457–66. 10.1093/protein/gzw040 27578889
Ridgway JB, Presta LG, Carter P., “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. (1996) 9:617–21. 8844834
Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. (2012) 119:6226–33. 10.1182/blood-2012-01-400515 22592608
Kontermann RE, Brinkmann U., Bispecific antibodies. Drug Discov Today. (2015) 20:838–47. 10.1016/j.drudis.2015.02.008 25728220
Pan H, Liu J, Deng W, Xing J, Li Q, Wang Z., Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy. Int J Nanomedicine. (2018) 13:3189–201. 10.2147/IJN.S164542 29881272
Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao S-W, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. (2015) 35:235–54. 10.3109/07388551.2013.834293 24156398
Stork R, Campigna E, Robert B, Muller D, Kontermann RE., Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. (2009) 284:25612–9. 10.1074/jbc.M109.027078 19628871
Hutt M, Farber-Schwarz A, Unverdorben F, Richter F, Kontermann RE., Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem. (2012) 287:4462–9. 10.1074/jbc.M111.311522 22147690
Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI., Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. (2019) 18:585–608. 10.1038/s41573-019-0028-1 31175342
Tita-Nwa F, Moldenhauer G, Herbst M, Kleist C, Ho AD, Kornacker M., Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother. (2007) 56:1911–20. 17487487
Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. (2017) 31:2181–90. 10.1038/leu.2017.41 28119525
Smits NC, Sentman CL., Bispecific T-Cell engagers (BiTEs) as treatment of B-cell lymphoma. J Clin Oncol. (2016) 34:1131–3.
Stieglmaier J, Benjamin J, Nagorsen D., Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther. (2015) 15:1093–9. 10.1517/14712598.2015.1041373 25971805
Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. (2008) 321:974–7. 10.1126/science.1158545 18703743
Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. (2015) 16:57–66. 10.1016/S1470-2045(14)71170-2 25524800
Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. (2015) 125:4024–31. 10.1182/blood-2014-12-614636 25887777
Pittari G, Filippini P, Gentilcore G, Grivel J-C, Rutella S., Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front Immunol. (2015) 6:230. 10.3389/fimmu.2015.00230 26029215
Chretien A-S, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, et al. Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity. Front Immunol. (2014) 5:122. 10.3389/fimmu.2014.00122 24715892
Selvaraj P, Carpen O, Hibbs ML, Springer TA., Natural killer cell and granulocyte Fc gamma receptor III (CD16) differ in membrane anchor and signal transduction. J Immunol. (1989) 143:3283–8. 2553809
Grzywacz B, Kataria N, Verneris MR., CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. (2007) 21:356–9; author reply 359.
Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. (2013) 121:3599–608. 10.1182/blood-2012-04-425397 23487023
Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. (2019) 177:1701–13.e16. 10.1016/j.cell.2019.04.041 31155232
Miller JS, Felice M, McElmurry R, McCullar V, Zhou X, Tolar J, et al. Trispecific killer engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion. Blood. (2015) 126:232.
Ilyas S, Yang JC., Landscape of tumor antigens in T cell immunotherapy. J Immunol. (2015) 195:5117–22. 10.4049/jimmunol.1501657 26589749
Valent P, Sadovnik I, Eisenwort G, Bauer K, Herrmann H, Gleixner KV, et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML. Int J Mol Sci. (2019) 20:4233. 10.3390/ijms20174233 31470642
Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, et al. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother. (2010) 59:1197–209. 10.1007/s00262-010-0844-y 20309546
Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. (2017) 31:383–95. 10.1016/j.ccell.2017.02.001 28262555
Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther. (2019) 106:781–91. 10.1002/cpt.1396 30770546
Paul S, Kantarjian H, Jabbour EJ., Adult acute lymphoblastic leukemia. Mayo Clin Proc. (2016) 91:1645–66. 10.1016/j.mayocp.2016.09.010 27814839
Rowe JM., Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. (2010) 150:389–405. 10.1111/j.1365-2141.2010.08246.x 20573154
Siegel R, Naishadham D, Jemal A., Cancer statistics, 2013. CA Cancer J Clin. (2013) 63:11–30. 10.3322/caac.21166 23335087
Chiaretti S, Zini G, Bassan R., Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. (2014) 6:e2014073. 10.4084/MJHID.2014.073 25408859
Wyatt KD, Bram RJ., Immunotherapy in pediatric B-cell acute lymphoblastic leukemia. Hum Immunol. (2019) 80:400–8. 10.1016/j.humimm.2019.01.011 30716352
Biondi A, Cazzaniga G., Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. Hematol Am Soc Hematol Educ Program. (2013) 2013:612–9. 10.1182/asheducation-2013.1.612 24319240
Pui C-H, Mullighan CG, Evans WE, Relling MV., Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. (2012) 120:1165–74. 10.1182/blood-2012-05-378943 22730540
Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, et al. Acute lymphoblastic leukemia, version 22015. J Natl Compr Canc Netw. (2015) 13:1240–79. 26483064
Tatar A-S, Nagy-Simon T, Tomuleasa C, Boca S, Astilean S., Nanomedicine approaches in acute lymphoblastic leukemia. J Control Release. (2016) 238:123–38. 10.1016/j.jconrel.2016.07.035 27460684
Scarfo L, Ferreri AJM, Ghia P., Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. (2016) 104:169–82. 10.1016/j.critrevonc.2016.06.003 27370174
Hallek M, Shanafelt TD, Eichhorst B., Chronic lymphocytic leukaemia. Lancet (London, England). (2018) 391:1524–37.
Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. (2011) 118:6904–8. 10.1182/blood-2011-08-373159 22039264
Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. (2012) 119:2854–62. 10.1182/blood-2011-12-395673 22308293
Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. (2013) 27:1100–6. 10.1038/leu.2012.357 23295735
Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. (1999) 59:24–7. 9892178
Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. (2000) 343:1910–6. 11136261
Gaidano G, Foa R, Dalla-Favera R., Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. (2012) 122:3432–8. 10.1172/JCI64101 23023714
Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. (2010) 17:28–40. 10.1016/j.ccr.2009.11.019 20060366
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood. (2008) 111:5446–56. 10.1182/blood-2007-06-093906 18216293
Brigle K, Rogers B., Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. (2017) 33:225–36. 10.1016/j.soncn.2017.05.012 28688533
Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer J. (2018) 8:123. 10.1038/s41408-018-0155-7 30470751
Caers J, Fernandez de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, et al. the changing landscape of smoldering multiple myeloma: a European perspective. Oncologist. (2016) 21:333–42. 10.1634/theoncologist.2015-0303 26921288
Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. (2010) 24:1121–7. 10.1038/leu.2010.60 20410922
Hakim O, Resch W, Yamane A, Klein I, Kieffer-Kwon K-R, Jankovic M, et al. DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes. Nature. (2012) 484:69–74. 10.1038/nature10909 22314321
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. (2015) 33:3911–20. 10.1200/JCO.2014.59.1503 26282654
Bianchi G, Munshi NC., Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. (2015) 125:3049–58. 10.1182/blood-2014-11-568881 25838343
Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. (2014) 5:2997. 10.1038/ncomms3997 24429703
Caers J, Garderet L, Martin Kortüm K, O’Dwyer ME, van de Donk NWCJ, Binder M, et al. An European myeloma network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when. Haematolgica. (2018) 103:1772–84.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. (2014) 15:e538–48.
Greipp PR, Miguel JS, Dune BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. (2005) 23:3412–20. 15809451
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. (2015) 33:2863–9. 10.1200/JCO.2015.61.2267 26240224
Dhodapkar MV, Borrello I, Cohen AD, Stadtmauer EA., Hematologic malignancies: plasma cell disorders. Am Soc Clin Oncol Educ Book. (2017) 37:561–8.
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F., Non-hodgkin lymphoma. Lancet (London, England). (2017) 390:298–310.
Smith A, Howell D, Patmore R, Jack A, Roman E., Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer. (2011) 105:1684–92. 10.1038/bjc.2011.450 22045184
Ninkovic S, Lambert J., Non-Hodgkin lymphoma. Medicine (Baltimore). (2017) 45:297–304.
Solimando AG, Ribatti D, Vacca A, Einsele H., Targeting B-cell non Hodgkin lymphoma: new and old tricks. Leuk Res. (2016) 42:93–104. 10.1016/j.leukres.2015.11.001 26818572
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. (2014) 32:3059–68. 25113753
Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. (2012) 30:980–8. 10.1200/JCO.2011.36.9348 22331940
Ahamadi-Fesharaki R, Fateh A, Vaziri F, Solgi G, Siadat SD, Mahboudi F, et al. Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow. Mol Ther Oncolytics. (2019) 14:38–56. 10.1016/j.omto.2019.02.004 31011631
Hammer O., CD19 as an attractive target for antibody-based therapy. MAbs. (2012) 4:571–7. 10.4161/mabs.21338 22820352
Wang K, Wei G, Liu D., CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. (2012) 1:36. 10.1186/2162-3619-1-36 23210908
Baeuerle PA, Kufer P, Bargou R., BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther. (2009) 11:22–30. 19169956
Nagorsen D, Kufer P, Baeuerle PA, Bargou R., Blinatumomab: a historical perspective. Pharmacol Ther. (2012) 136:334–42. 10.1016/j.pharmthera.2012.07.013 22940266
Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. (2014) 32:4134–40. 10.1200/JCO.2014.56.3247 25385737
Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. (2011) 29:2493–8. 10.1200/JCO.2010.32.7270 21576633
Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler M-E, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. (2012) 120:5185–7. 10.1182/blood-2012-07-441030 23024237
Przepiorka D, Ko C-W, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu H-J, et al. FDA Approval: Blinatumomab. Clin Cancer Res. (2015) 21:4035–9. 10.1158/1078-0432.CCR-15-0612 26374073
Portell CA, Wenzell CM, Advani AS., Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. (2013) 5(Suppl. 1):5–11. 10.2147/CPAA.S42689 23671399
Liu L, Lam C-YK, Long V, Widjaja L, Yang Y, Li H, et al. MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B-cell malignancies. Clin Cancer Res. (2017) 23:1506–18. 10.1158/1078-0432.CCR-16-0666 27663593
Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. (2015) 7:584–604. 10.1080/19420862.2015.1029216 25875246
Buhmann R, Michael S, Juergen H, Horst L, Peschel C, Kolb H-J., Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven. J Transl Med. (2013) 11:160. 10.1186/1479-5876-11-160 23815981
Kieslich A, Ruf P, Lindhofer H, Buhmann R, Eggert A, Hundsdoerfer P., Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. Leuk Lymphoma. (2017) 58: 1989–92.
Schuster FR, Stanglmaier M, Woessmann W, Winkler B, Siepermann M, Meisel R, et al. Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies. Br J Haematol. (2015) 169:90–102. 10.1111/bjh.13242 25495919
Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep. (2015) 5:17943. 10.1038/srep17943 26659273
Bannerji R, Brown JR, Advani RH, Arnason J, O’Brien SM, Allan JN, et al. Phase 1 study of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, in patients with CD20+ B-cell malignancies previously treated with CD20-directed antibody therapy. Blood. (2016) 128:621.
Schuster SJ, Bartlett NL, Assouline S, Yoon S-S, Bosch F, Sehn LH, et al. Mosunetuzumab induces complete remissions in poor prognosis Non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. (2019) 134(Suppl. 1):6.
Bacac M, Umaña P, Herter S, Colombetti S, Sam J, Le Clech M, et al. CD20 Tcb (RG6026), a Novel “2:1” T Cell Bispecific Antibody for the Treatment of B Cell Malignancies. Blood. (2016) 128:1836.
Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs. (2014) 6:728–39. 10.4161/mabs.28591 24670809
Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res. (2018) 24:4785–97. 10.1158/1078-0432.CCR-18-0455 29716920
Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F., CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med. (2008) 14:210–8. 10.1016/j.molmed.2008.02.005 18403265
Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL, et al. Targeting multiple myeloma with AMG 424, a novel Anti-CD38/CD3 bispecific t-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res. (2019) 25:3921–33. 10.1158/1078-0432.CCR-18-2752 30918018
Chu SY, Miranda Y, Phung S, Chen H, Rashid R, Endo NA, et al. Immunotherapy with long-lived Anti-CD38 × Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD38+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood. (2014) 124:4727.
Tai Y-T, Anderson KC., Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. (2015) 7:1187–99. 10.2217/imt.15.77 26370838
Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. (2013) 19:2048–60. 10.1158/1078-0432.CCR-12-2422 23344265
O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. (2004) 199:91–8. 14707116
Hipp S, Tai Y-T, Blanset D, Deegen P, Wahl J, Thomas O, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. (2017) 31:1743–51. 10.1038/leu.2016.388 28025583
Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. (2017) 31:396–410. 10.1016/j.ccell.2017.02.002 28262554
Costa LJ, Wong SW, Bermúdez A, de la Rubia J, Mateos M-V, Ocio EM, et al. First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. (2019) 134(Suppl. 1):143.
Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L, et al. Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol Cancer Ther. (2019) 18:2008–20. 10.1158/1535-7163.MCT-19-0007 31434693
Lesokhin AM, Raje N, Gasparetto CJ, Walker J, Krupka HI, Joh T, et al. A Phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen/CD3 bispecific antibody, in patients with relapsed/refractory advanced multiple myeloma. Blood. (2018) 132(Suppl. 1):3229.
Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol. (2006) 18:1363–73. 16849395
Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. (2007) 21:169–74. 17051241
Kodama T, Kochi Y, Nakai W, Mizuno H, Baba T, Habu K, et al. Anti-GPRC5D/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. (2019) 18:1555–64. 10.1158/1535-7163.MCT-18-1216 31270154
Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. (2012) 42:953–60. 10.1111/j.1365-2362.2012.02679.x 22591013
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. (2014) 124:188–95. 10.1182/blood-2014-05-552729 24876563
Li J, Piskol R, Ybarra R, Chen Y-JJ, Li J, Slaga D, et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. (2019) 11:eaax8861. 10.1126/scitranslmed.aax8861 31484792
Tanaka T, Narazaki M, Kishimoto T., Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. (2016) 8:959–70. 10.2217/imt-2016-0020 27381687
Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. (2018) 6:56. 10.1186/s40425-018-0343-9 29907163
Barrett DM, Teachey DT, Grupp SA., Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. (2014) 26:43–9. 10.1097/MOP.0000000000000043 24362408
Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Muller S, et al. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci USA. (2003) 100:14145–50. 14610278
Sibener LV, Fernandes RA, Kolawole EM, Carbone CB, Liu F, McAffee D, et al. Isolation of a structural mechanism for uncoupling T cell receptor signaling from peptide-MHC binding. Cell. (2018) 174:672–87.e27. 10.1016/j.cell.2018.06.017 30053426
Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. MAbs. (2019) 11:639–52. 10.1080/19420862.2019.1574521 30698484
Magge RS, DeAngelis LM., The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. (2015) 29:93–100. 10.1016/j.blre.2014.09.012 25445718
Goebeler M-E, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-hodgkin lymphoma: final results from a phase I study. J Clin Oncol. (2016) 34:1104–11. 10.1200/JCO.2014.59.1586 26884582
Brandl C, Haas C, d’Argouges S, Fisch T, Kufer P, Brischwein K, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother. (2007) 56:1551–63. 17310380
Woo S-R, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. (2012) 72:917–27. 10.1158/0008-5472.CAN-11-1620 22186141
Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. (2014) 26:923–37. 10.1016/j.ccell.2014.10.018 25465800
Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. (2006) 443:350–4. 16921384
Ruella M, Maus MV., Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. (2016) 14:357–62. 27761200
Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen E-M, Koristka S, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia. (2014) 28:59–69. 10.1038/leu.2013.243 23958923
Liu R, Jiang W, Yang M, Guo H, Zhang Y, Wang J, et al. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies. J Immunother. (2010) 33:500–9. 10.1097/CJI.0b013e3181d75c20 20463597
Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, et al. Engineering of Anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity. Cancer Res Treat. (2017) 49:1140–52. 10.4143/crt.2016.491 28231426
Khan S, Gerber DE., Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. (2019) S1044-579X(19)30019-7. 10.1016/j.semcancer.2019.06.012 31330185
Braig F, Brandt A, Goebeler M, Tony H-P, Kurze A-K, Nollau P, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. (2017) 129:100–4. 10.1182/blood-2016-05-718395 27784674
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. (2015) 5:1282–95. 10.1158/2159-8290.CD-15-1020 26516065
Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, et al. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clin Cancer Res. (2015) 21:1267–72. 10.1158/1078-0432.CCR-14-2877 25770294
Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol. (2012) 188:1551–8. 10.4049/jimmunol.1101760 22184723
Pardoll DM., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. (2012) 12:252–64. 10.1038/nrc3239 22437870
Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. (2016) 30:484–91. 10.1038/leu.2015.214 26239198
Knaus HA, Kanakry CG, Luznik L, Gojo I., Immunomodulatory drugs: immune checkpoint agents in acute leukemia. Curr Drug Targets. (2017) 18:315–31. 10.2174/1389450116666150518095346 25981611
Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. (2017) 35:709–17. 10.1200/JCO.2016.68.2005 27646942
Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. (2017) 35:785–92. 10.1200/JCO.2015.66.1389 28068177
Tajiri K, Aonuma K, Sekine I., Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. (2018) 48:7–12. 10.1093/jjco/hyx154 29045749
Feucht J, Kayser S, Gorodezki D, Hamieh M, Doring M, Blaeschke F, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget. (2016) 7:76902–19. 10.18632/oncotarget.12357 27708227
Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia. (2018) 32:1239–43.
La Motte-Mohs R, Shah K, Smith DH, Gorlatov S, Ciccarone V, Tamura J, et al. Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 dual-affinity Re-targeting (DART§) protein with T-cell Immunomodulatory activity for cancer treatment. Am Assoc Cancer Res Annu Meet. (2016) 76(14 Suppl.): 3217.
Dovedi SJ, Mazor Y, Elder M, Hasani S, Wang B, Mosely S, et al. Abstract 2776: MEDI5752: a novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells. Cancer Res. (2018) 78(13 Suppl.):2776.
Ye Q, Song D-G, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. (2014) 20:44–55. 10.1158/1078-0432.CCR-13-0945 24045181
Houot R, Kohrt H, Levy R., Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology. (2012) 1:957–8. 23162770
Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcgammaR affinity. Nat Commun. (2019) 10:2141. 10.1038/s41467-019-10088-1 31105267
Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, et al. Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. (2017) 23:5349–57. 10.1158/1078-0432.CCR-17-1243 28634283
Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. Results from an integrated safety analysis of urelumab, an agonist Anti-CD137 monoclonal antibody. Clin Cancer Res. (2017) 23:1929–36. 10.1158/1078-0432.CCR-16-1272 27756788
Eskiocak U, Guzman W, Wolf B, Cummings C, Milling L, Wu H-J, et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. (2020) 5:e133647. 10.1172/jci.insight.133647 32161196
Mikkelsen K, Harwood SL, Compte M, Merino N, Molgaard K, Lykkemark S, et al. Carcinoembryonic antigen (CEA)-specific 4-1BB-costimulation induced by CEA-targeted 4-1BB-agonistic trimerbodies. Front Immunol. (2019) 10:1791. 10.3389/fimmu.2019.01791 31417564
Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, Durr MC, Schlosser C, et al. Tumor-localized costimulatory T-cell engagement by the 4-1BB/HER2 bispecific antibody-anticalin fusion PRS-343. Clin Cancer Res. (2019) 25:5878–89. 10.1158/1078-0432.CCR-18-3654 31138587
Van Blarcom T, Lindquist K, Melton Z, Cheung WL, Wagstrom C, McDonough D, et al. Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies. MAbs. (2018) 10:256–68. 10.1080/19420862.2017.1406570 29227213
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. (2019) 11:eaav5989. 10.1126/scitranslmed.aav5989 31189721
Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. (2009) 138:271–85. 10.1016/j.cell.2009.05.046 19632178
Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. (2015) 21:1209–15. 10.1038/nm.3931 26322579
Subramanian S, Parthasarathy R, Sen S, Boder ET, Discher DE., Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood. (2006) 107:2548–56. 16291597
Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. (2017) 25:523–33. 10.1016/j.ymthe.2016.11.006 28153099
van Bommel PE, He Y, Schepel I, Hendriks MAJM, Wiersma VR, van Ginkel RJ, et al. CD20-selective inhibition of CD47-SIRPalpha “don’t eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. Oncoimmunology. (2018) 7:e1386361.
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. (2007) 356:2582–90. 17582068
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K., Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. (2017) 16:41–50. 10.1016/j.ebiom.2017.01.042 28161400
Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, et al. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. (2001) 10:247–60. 11359672
Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA. (2011) 108:11187–92. 10.1073/pnas.1019002108 21690412
Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, et al. Engineering therapeutic bispecific antibodies using CrossMab technology. Methods. (2019) 154:21–31. 10.1016/j.ymeth.2018.11.008 30453028
Tustian AD, Endicott C, Adams B, Mattila J, Bak H., Development of purification processes for fully human bispecific antibodies based upon modification of protein a binding avidity. MAbs. (2016) 8:828–38. 10.1080/19420862.2016.1160192 26963837
Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K-M, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel. (2010) 23:195–202. 10.1093/protein/gzp094 20299542
Geuijen CAW, De Nardis C, Maussang D, Rovers E, Gallenne T, Hendriks LJA, et al. Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade. Cancer Cell. (2018) 33:922–36.e10. 10.1016/j.ccell.2018.04.003 29763625
De Nardis C, Lossl P, van den Biggelaar M, Madoori PK, Leloup N, Mertens K, et al. Recombinant expression of the full-length ectodomain of LDL receptor-related protein 1 (LRP1) unravels pH-dependent conformational changes and the stoichiometry of binding with receptor-associated protein (RAP). J Biol Chem. (2017) 292:912–24. 10.1074/jbc.M116.758862 27956551
Moore GL, Bernett MJ, Rashid R, Pong EW, Nguyen D-HT, Jacinto J, et al. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats. Methods. (2019) 154:38–50. 10.1016/j.ymeth.2018.10.006 30366098
Labrijn AF, Meesters JI, de Goeij BECG, van den Bremer ETJ, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci USA. (2013) 110:5145–50. 10.1073/pnas.1220145110 23479652
Stanglmaier M, Faltin M, Ruf P, Bodenhausen A, Schroder P, Lindhofer H., Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer. (2008) 123:1181–9. 10.1002/ijc.23626 18546289
Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. (2000) 95:2098–103. 10706880
Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, et al. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol. (2005) 130:218–28. 16029450
Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX., Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. (2012) 11:2674–84. 10.1158/1535-7163.MCT-12-0692 23075808
Brusselbach S, Kom T, Volkel T, Muller R, Kontermann RE., Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Target. (1999) 4:115–23.
Topp MS, Attal M, Langer C, Moreau P, Facon T, Düll J, et al. Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM). J Clin Oncol. (2016) 34(15 Suppl.):TS8067.
Cho S-F, Lin L, Xing L, Wen K, Yu T, Wahl J, et al. AMG 701, a half-life extended anti-BCMA BiTE§, potently induces T cell-redirected lysis of human multiple myeloma cells and can be combined with IMiDs to overcome the immunosuppressive bone marrow microenvironment. Clin Lymphoma Myeloma Leuk. (2019) 19:e54.
Girgis S, Shetty S, Jiao T, Amuzie C, Weinstock D, Watson RG, et al. Exploratory pharmacokinetic/pharmacodynamic and tolerability study of BCMAxCD3 in cynomolgus monkeys. Blood. (2016) 128:5668.
Dilillo DJ, Olson K, Mohrs K, Meagher TC, Bray K, Sineshchekova O, et al. REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to that of BCMA CAR T Cells. Blood. (2018) 132(Suppl. 1):1944.
Richter JR, Wermke M, Kauh JS, Back J, Salhi Y, Reddy V, et al. Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma. J Clin Oncol. (2018) 36(5 Suppl.):TS81.
Chu SY, Pong E, Hsing C, Phung S, Chan EW, Endo NA, et al. Immunotherapy with long-lived Anti-CD123 × Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood. (2014) 124:2316.
Ravandi F, Bashey A, Foran JM, Stock W, Mawad R, Blum W, et al. Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study. Blood. (2018) 132(Suppl. 1):763.
Cui Y, Huang Z, Zhang X, Shen W, Chen H, Wen Z, et al. CD3-activating Bi-specific antibody targeting CD19 on B cells in Mono- and Bi-valent format. Blood. (2018) 132(Suppl. 1):4169.
Popplewell L, Verhoef G, Kuruvilla J, Tuglus C, Kischel R, Stieglmaier J, et al. A first-in-human study of a half-life extended CD19-targeting BiTE in relapsed-refractory diffuse large B cell lymphoma, mantle cell lymphoma or follicular lymphoma. Hematol Oncol. (2019) 37(S2):566–7.
Pratz K, Gojo I, Gocke C, Matsui W, Huff C., Blinatumomab induced response of multiply refractory multiple myeloma in the context of secondary Pre-B cell acute lymphoblastic leukemia. Ann Hematol Oncol. (2017) 4:1174.
Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, et al. Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with Non-Hodgkin lymphoma. Curr Clin Pharmacol. (2018) 13:55–64. 10.2174/1574884713666180518102514 29773068
Hiemstra I, Engelberts P, de Jong B, Schuurhuis D, Salcedo T, Verploegen S, et al. Potent anti-tumor activity of duobody-CD3XCD20 in preclinical models in vitro and in vivo. HemaSphere. (2019) 3:594. 10.1016/j.ebiom.2019.102625 31981978
Ferl GZ, Reyes A, Sun LL, Cheu M, Oldendorp A, Ramanujan S, et al. A preclinical population pharmacokinetic model for Anti-CD20/CD3 T-cell-dependent bispecific antibodies. Clin Transl Sci. (2018) 11:296–304. 10.1111/cts.12535 29351372
Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. (2015) 7:287ra70. 10.1126/scitranslmed.aaa4802 25972002
Chu SY, Lee S-H, Rashid R, Hsing C, Chan EW, Phung S, et al. Immunotherapy with long-lived Anti-CD20 × Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human B cell lines and of circulating and lymphoid B cells in monkeys: a potential therapy for B cell lymphomas and leukemias. Blood. (2014) 124: 31111.
Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, et al. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin’s lymphoma: a pilot study. Bone Marrow Transplant. (2014) 49:73–9. 10.1038/bmt.2013.133 24056738
Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, et al. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. (2013) 19:925–33. 10.1016/j.bbmt.2013.03.010 23529012
Wu J, Fu J, Zhang M, Liu D., AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. (2015) 8:96. 10.1186/s13045-015-0188-3 26231785
Eckelman BP, Timmer JC, Hata C, Jones KS, Hussain A, Razai AS, et al. Multivalent and Multispecific 41BB-Binding Fusion Proteins. Patent No. US 2017/0198050 A1. San Diego, CA: Inhibrx. (2017).
Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP., Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. (2009) 33:1233–42. 10.1016/j.leukres.2009.02.006 19327829
Coward J, Ganju V, Behzadigohar R, Kwong K, Xu J, Van H, et al. Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors. J Clin Oncol. (2019) 37(15 Supp.):2554.
Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia. Mol Cancer Ther. (2018) 17:1739–51. 10.1158/1535-7163.MCT-17-1095 29743205